Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HCA-N Solution for the Preservation of Kidney Grafts During Kidney Transplantation
NCT07825025Phase 3
Key facts
- Status
- Active, not recruiting
- Start
- Dec 2025
- Primary completion
- Apr 2028
- Countries
- 1
- Sponsor
- Zhongnan Hospital of Wuhan University
- Drugs
- HCA-N Solution
- Conditions
- kidney transplantation
01
Overview
Phase 3, randomised, double-blind trial of HCA-N Solution in kidney transplantation (2 arms), sponsored by Zhongnan Hospital of Wuhan University. Primary endpoint: Delayed Graft Function at Day 28. Started Dec 2025; status: active, not recruiting.
02
Design
2 arms- Study design
- RandomizedDouble-blind
HCA-N Solution
Donor kidney flushed and preserved using HCA-N Solution.
HTK Solution
Donor kidney flushed and preserved using HTK Solution.
03
Who it enrols
Recipients must be 18-65 years old, eligible for first-time allogeneic renal transplantation, and have no history of previous organ transplantation, severe concurrent diseases, or recent malignancies. Donors must be 18-65 years old with serum creatinine < 2 mg/dL and no prior hemodialysis.
04
Endpoints
Primary
Delayed Graft Function
Beyond the preview
Go deeper on NCT07825025.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07825025.